Page last updated: 2024-08-25

7-hydroxystaurosporine and melphalan

7-hydroxystaurosporine has been researched along with melphalan in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Dai, Y; Dent, P; Grant, S; Landowski, TH; Rosen, ST	1

Other Studies

2 other study(ies) available for 7-hydroxystaurosporine and melphalan

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood, 2002, Nov-01, Volume: 100, Issue:9 Topics: Alkaloids; Apoptosis; Benzamides; Bone Marrow Cells; CDC2 Protein Kinase; Cell Adhesion; Cell Cycle; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Free Radical Scavengers; Humans; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melphalan; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Syndecan-1; Syndecans; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002

Article

Year

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008

Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

Blood, 2002, Nov-01, Volume: 100, Issue:9

Topics: Alkaloids; Apoptosis; Benzamides; Bone Marrow Cells; CDC2 Protein Kinase; Cell Adhesion; Cell Cycle; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Free Radical Scavengers; Humans; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melphalan; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Syndecan-1; Syndecans; Tumor Cells, Cultured; Tumor Stem Cell Assay

2002